Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)

The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underreported complication of Allogeneic Stem Cell Transplant (SCT). The main question it aims to answer is: What is the incidence of TA-TMA in adults undergoing SCT? How does TA-TMA diagnosis impact survival and other outcomes? Patients undergoing SCT will be eligible for this study, which will consist of collection of biological samples and standard clinical follow up.

NCT Number	NCT07381205
Lead Sponsor	Manuel Ricardo Espinoza-Gutarra Collaborators: BMS Foundation, Viracor Eurofins, Robert A. Winn Diversity in Clinical Trials Award Program
Conditions	Transplant Associated Microangiopathy TAM, Transplant Complication
Enrollment	85 participants
Start Date	2026-08-01
Primary Completion	2027-11 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-06